Understand the source comparison
Best Peptides for Peripheral Artery Disease: Research Compound Comparison
BPC-157 VEGF upregulation, eNOS activation, endothelial repair 200–500 mcg/day subcutaneous 4–6 hours Preclinical animal models show 40% improvement in blood flow recovery vs controls Strongest mechanistic evidence for direct angiogenesis. Short half-life requ
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, eNOS activation, endothelial repair
- 200–500 mcg/day subcutaneous
- 4–6 hours
- Preclinical animal models show 40% improvement in blood flow recovery vs controls
- Strongest mechanistic evidence for direct angiogenesis. Short half-life requires split dosing
- TB-500
- Actin binding, endothelial cell migration, collateral vessel formation
- 2–5 mg twice weekly (loading), 2 mg weekly (maintenance)
- ~10 days
- Preclinical models demonstrate increased capillary density in ischemic tissue
- Longer half-life supports less frequent dosing. Evidence focused on structural repair
- Thymalin
- Immune modulation, reduction of pro-inflammatory cytokines (TNF-alpha, IL-6)
- 5–10 mg 2–3x weekly
- Variable
- Limited direct vascular evidence. Primarily studied for immune regulation
- Addresses inflammatory component of PAD progression. Not a primary angiogenic agent